Allodynia News and Research

RSS

Allodynia, meaning "other pain", is a painful (noxious) response to a usually non-painful (innocuous) stimulus and can be either static or mechanical. Allodynia differs from referred pain, but can occur in areas other than the one stimulated. It is dysesthetic. Allodynia is different from hyperalgesia, an extreme reaction to a stimulus which is normally painful.

MAP Pharmaceuticals reports net loss of $12.5M for second-quarter 2010

MAP Pharmaceuticals, Inc. today announced financial results for the second quarter ended June 30, 2010.

3 Aug 2010

MAP Pharmaceuticals reports results from LEVADEX PK and safety clinical trial in smokers, non-smokers

MAP Pharmaceuticals, Inc. today announced results from a clinical trial comparing the pharmacokinetics (PK) and safety of LEVADEX™ orally inhaled migraine therapy with intravenous dihydroergotamine mesylate (DHE) in smokers and non-smokers. The trial was designed to measure whether systemic absorption and exposure in smokers is greater than in non-smokers. In the trial, the systemic absorption of LEVADEX was not higher and systemic exposure to DHE was not greater in smokers than in non-smokers.

13 Jul 2010

Laboratory mouse study shows cold sensing neural circuits develop well after birth

Cold sensing neural circuits in newborn mice take around two weeks to become fully active, according to a new study. The finding adds to understanding of the cold sensing protein TRPM8 (pronounced trip-em-ate), first identified in a Nature paper in 2002 by David McKemy of the University of Southern California.

18 Jun 2010

MAP Pharmaceuticals to present additional data from FREEDOM-301 Phase 3 trial of LEVADEX at AAN meeting

MAP Pharmaceuticals, Inc. today announced the Company will present additional post-hoc analyses from the FREEDOM-301 Phase 3 trial of its investigational LEVADEX™ orally inhaled migraine therapy in two patient subpopulations that are often difficult to treat with current triptan migraine therapies: menstrual migraine and migraine with allodynia.

7 Apr 2010

Raptor Pharmaceutical announces results of NGX426 clinical trial

Raptor Pharmaceutical Corp. today announced the presentation of clinical trial data on NGX426, the Company's orally administered, non-opioid, AMPA/kainate receptor antagonist, at the 12th International Conference on the Mechanisms and Treatment of Neuropathic Pain, held on November 20-21 in San Francisco.

23 Nov 2009

Positive results from KAI Pharmaceuticals' pain therapeutic program

KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, announced positive preclinical results from its program targeting the gamma protein kinase C (PKC) pathway for the development of novel therapies for pain.

20 Oct 2009

Phase 3 trial results of LEVADEX orally inhaled migraine therapy to be presented

MAP Pharmaceuticals, Inc. announced today that it will present analysis of data from the efficacy portion of the first Phase 3 trial of its novel LEVADEX orally inhaled migraine therapy, currently in development, at the 14th Congress of the International Headache Society.

11 Sep 2009

Endocannabinoids found to spread and prolong pain

Imagine that you're working on your back porch, hammering in a nail. Suddenly you slip and hit your thumb instead - hard. The pain is incredibly intense, but it only lasts a moment. After a few seconds (and a few unprintable words) you're ready to start hammering again.

13 Aug 2009

Compound from coral offers hope fpr neuropathic pain

A compound initially isolated from a soft coral (Capnella imbricata) collected at Green Island off Taiwan, could lead scientists to develop a new set of treatments for neuropathic pain - chronic pain that sometimes follows damage to the nervous system.

4 Aug 2009

Common migraine pain condition allodynia also prevalent in cluster headache

A pain condition common in people with migraines also has a high prevalence in patients with cluster headache, according to a study conducted by researchers at the Jefferson Headache Center at Jefferson Hospital for Neuroscience.

27 May 2009

KAI Pharmaceuticals reports positive results for KAI-1678 in pain reduction

KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, today announced preclinical results demonstrating the effectiveness of KAI-1678 in reversing pain (hyperalgesia and allodynia) in multiple preclinical models.

19 Nov 2008

MRI reveals relationship between depression and pain

The brains of individuals with major depressive disorder appear to react more strongly when anticipating pain and also display altered functioning of the neural network that modifies pain sensitivity, according to a report in the November issue of Archives of General Psychiatry , one of the JAMA/Archives journals.

4 Nov 2008

Migraine exacerbates skin sensitivity or pain

People with migraine are more likely to experience exacerbated skin sensitivity or pain after non-painful daily activities such as rubbing one's head, combing one's hair and wearing necklaces or earrings, compared to people with other types of headache, according to a study published in the April 22, 2008, issue of Neurology, the medical journal of the American Academy of Neurology.

21 Apr 2008

Migraine sufferers found to have brain differences

According to new research from the U.S., migraine sufferers have structural differences in the part of the brain that deals with pain.

20 Nov 2007

People with migraines have differences in cortex area of the brain

People with migraines have differences in an area of the brain that helps process sensory information, including pain, according to a study published in the November 20, 2007, issue of Neurology, the medical journal of the American Academy of Neurology.

19 Nov 2007

Why the cold hurts - research has implications for pain relief

Freeing knotted shoelaces with fingers that are frozen stiff is extremely difficult and can even be painful.

20 Jun 2007

Hearing protein TRPA1 also involved with pain perception

The same protein that “translates” sound into nerve signals to the brain and enables individuals to hear is also required for pain perception, researchers from Northwestern University Feinberg School of Medicine have found.

21 Jul 2005

Stronger version of chickenpox vaccine cuts incidence and severity of shingles in older adults

In one of the largest adult vaccine clinical trials ever, researchers have found that an experimental vaccine against shingles (zoster vaccine) prevented about half of cases of shingles--a painful nerve and skin infection--and dramatically reduced its severity and complications in vaccinated persons who got the disease. The findings appear in the June 2 issue of The New England Journal of Medicine.

1 Jun 2005

Scientists develop a way to block the signals responsible for neuropathic pain

Remember how it felt the last time you burned your finger on a hot stove? Imagine what it's like to have that burning pain in your hands or feet all the time and know there's virtually nothing you can do about it.

1 Jun 2005

Protein TRPA1 essential for hearing also vital for pain perception

The same protein that "translates" sound into nerve signals to the brain and enables individuals to hear is also required for pain perception, researchers from Northwestern University Feinberg School of Medicine have found.

25 May 2005